Guggenheim raises Septerna stock price target to $65 on pipeline progress

Investing.com reports that Guggenheim has increased its price target on Septerna Inc shares to $65 from $51, while maintaining a Buy rating. The firm has raised its probability of success for the company's oral small molecule PTH replacement SEP-479 to 50% from 35%. Additionally, Guggenheim has incorporated risk-adjusted sales estimates for SEP-204, a Graves' disease treatment, into its model with a 10% probability of success.

Septerna's stock has risen 70% year-to-date, surpassing the XBI biotech index's 22% gain and the S&P 500's 7% increase. The company's Graves' disease asset is set to enter the clinic in the first quarter of 2027, ahead of expectations.